DNA repair disease
MONDO:0021190A disease that has its basis in the disruption of DNA repair.
Also known as: DNA repair disorder, deficiency of DNA repair, disorder of DNA repair, DNA Repairs, deficient, DNA repair deficiency, DNA repair deficiency disorders, DNA repair, deficient, DNA repair-deficiencies
105 clinical trials for this condition and its sub-types, 13 tagged with DNA repair disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of DNA repair disease
-
Fanconi anemia 29 trials · 42 incl. sub-types
22 sub-types
- Fanconi anemia complementation group D1 6 trials
- Fanconi anemia complementation group A 4 trials
- Fanconi anemia complementation group E 4 trials
- Fanconi anemia complementation group N 2 trials
- Fanconi anemia, complementation group S 2 trials
- Fanconi anemia complementation group B 0 trials
- Fanconi anemia complementation group C 0 trials
- Fanconi anemia complementation group D2 0 trials
- Fanconi anemia complementation group F 0 trials
- Fanconi anemia complementation group G 0 trials
- Fanconi anemia complementation group I 0 trials
- Fanconi anemia complementation group J 0 trials
- Fanconi anemia complementation group L 0 trials
- Fanconi anemia complementation group O 0 trials
- Fanconi anemia complementation group P 0 trials
- Fanconi anemia complementation group Q 0 trials
- Fanconi anemia complementation group R 0 trials
- Fanconi anemia complementation group T 0 trials
- Fanconi anemia complementation group U 0 trials
- Fanconi anemia complementation group V 0 trials
- Fanconi anemia, complementation group W 0 trials
- Fanconi anemia, complementation group 10 0 trials
-
Mismatch repair cancer syndrome 5 trials · 36 incl. sub-types
4 sub-types
- Mismatch repair cancer syndrome 1 34 trials
- Mismatch repair cancer syndrome 2 0 trials
- Mismatch repair cancer syndrome 3 0 trials
- Mismatch repair cancer syndrome 4 0 trials
-
Cockayne syndrome 6 trials
4 sub-types
- Cockayne spectrum with or without cerebrooculofacioskeletal syndrome 0 trials
- Cockayne syndrome type 1 0 trials
- Cockayne syndrome type 2 0 trials
- Cockayne syndrome type 3 0 trials
-
Xeroderma pigmentosum 4 trials · 6 incl. sub-types
10 sub-types
- Xeroderma pigmentosum group F 1 trial
- Xeroderma pigmentosum variant type 1 trial
- Xeroderma pigmentosum group A 0 trials
- Xeroderma pigmentosum group B 0 trials
- Xeroderma pigmentosum group C 0 trials
- Xeroderma pigmentosum group D 0 trials
- Xeroderma pigmentosum group E 0 trials
- Xeroderma pigmentosum group G 0 trials
- Xeroderma pigmentosum, autosomal dominant, mild 0 trials
- Xeroderma pigmentosum, complementation group J 0 trials
-
Karyomegalic interstitial nephritis 2 trials
-
Spinocerebellar ataxia, autosomal recessive, with axonal neuropathy 0 trials · 2 incl. sub-types
-
COFS syndrome 1 trial
5 sub-types
- Cerebrooculofacioskeletal syndrome 1 0 trials
- Cerebrooculofacioskeletal syndrome 2 0 trials
- Cerebrooculofacioskeletal syndrome 3 0 trials
- Cerebrooculofacioskeletal syndrome 4 0 trials
- Xeroderma pigmentosum group G 0 trials
-
Nijmegen breakage syndrome 1 trial
-
UV-sensitive syndrome 0 trials
3 sub-types
- UV-sensitive syndrome 1 0 trials
- UV-sensitive syndrome 2 0 trials
- UV-sensitive syndrome 3 0 trials
-
Photosensitive trichothiodystrophy 0 trials
3 sub-types
- Trichothiodystrophy 1, photosensitive 0 trials
- Trichothiodystrophy 2, photosensitive 0 trials
- Trichothiodystrophy 3, photosensitive 0 trials
-
Immunotherapy combo aims to prevent colon cancer return in High-Risk patients
Disease control OngoingThis phase 3 trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy can help prevent cancer from coming back in people with stage III colon cancer that has a specific DNA repair defect (dMMR). About 712 participants will receive either chemo …
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New combo therapy targets cancer's DNA repair weakness
Disease control OngoingThis study tests a combination of two drugs, avelumab and M6620, in people with advanced solid tumors that have spread or can't be removed by surgery. The tumors must have a specific DNA repair defect. The goal is to find the safest dose and see if the combination can help contro…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New hope for tough prostate cancer: targeted drug combo shows promise
Disease control OngoingThis study tests two drugs—abiraterone and olaparib—alone or together in men with advanced prostate cancer that has spread and no longer responds to hormone therapy. Only men whose tumors have certain DNA repair defects (like BRCA or ATM mutations) are included. The goal is to se…
Phase 2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Immunotherapy combo shows promise for Hard-to-Treat stomach cancers
Disease control OngoingThis phase II trial is testing whether giving the immunotherapy drug pembrolizumab before standard chemotherapy and radiation can help prevent stomach cancer from coming back. It includes 40 people with operable stomach cancer that has either a specific DNA repair problem (mismat…
Phase 2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Lung cancer clue: could a DNA glitch open door to new treatments?
Knowledge-focused OngoingThis study looks at a specific DNA repair issue called homologous recombination deficiency (HRD) in people with a type of lung cancer (EGFR-mutated NSCLC). Researchers want to know how common HRD is and whether it relates to how the cancer behaves. They will also test this in lab…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:07 UTC